Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 bln
06:51am, Monday, 08'th Jan 2024
Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.
TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating resu
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
11:18am, Friday, 05'th Jan 2024
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?
01:32pm, Wednesday, 03'rd Jan 2024
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?
12:01pm, Wednesday, 03'rd Jan 2024
Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in
Top 5 Momentum Picks for January After a Fabulous 2023
09:46am, Wednesday, 03'rd Jan 2024
We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
09:01am, Wednesday, 03'rd Jan 2024
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.
2 gene-editing stocks reshaping hereditary disease treatments
07:16am, Tuesday, 02'nd Jan 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle
Where Will Regeneron Pharmaceuticals Be in 1 Year?
09:45am, Friday, 22'nd Dec 2023
The recent launch of Eylea HD should lead to stronger sales growth for Regeneron next year. The company's hematology-oncology business could get a boost with a possible drug approval.
7 Undervalued Nasdaq-100 Stocks for Bargain Hunters
08:15pm, Thursday, 21'st Dec 2023
Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks. Indeed, on a year-to-date basis, the index shot up about 52%.
5 Big Drug Stocks That May Continue to Outperform in 2024
10:31am, Monday, 18'th Dec 2023
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
05:00am, Sunday, 17'th Dec 2023
Coca-Cola offers investors the security of growing dividend payments. Alphabet and Regeneron have delivered long track records of growth -- and more is on the way.
Wells Fargo's top pharma picks for 2024
05:33pm, Friday, 15'th Dec 2023
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)
01:56pm, Thursday, 14'th Dec 2023
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) American Society of Hematology 2023 Investor Conference Call December 14, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relat
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
01:32pm, Friday, 08'th Dec 2023
Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
